Document is current
Any future updates will be listed below
-
Authors
Gao, Jing
Wang, Zhengyi
Jiang, Wenqing
Zhang, Yanni
Meng, Zhen
Niu, Yanling
Sheng, Zhen
Chen, Chan
Liu, Xuejun
Chen, Xi
Liu, Chanjuan
Jia, Keren https://orcid.org/0000-0001-6577-0573
Zhang, Cheng
Liao, Haiyan
Jung, Jaeho
Sung, Eunsil
Chung, Hyejin
Zhang, Jingwu Z.
Zhu, Andrew X.
Shen, Lin https://orcid.org/0000-0002-8798-4756
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04900818 at ClinicalTrials.govDocuments that mention this clinical trial
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
https://doi.org/10.1136/jitc-2023-006704
702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies
https://doi.org/10.1136/jitc-2021-sitc2021.702
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82072728)
- License Information
